{"id":"https://openalex.org/W2249078564","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.2512","title":"Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.","display_name":"Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.","publication_year":2012,"publication_date":"2012-05-20","ids":{"openalex":"https://openalex.org/W2249078564","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.2512","mag":"2249078564"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2012.30.15_suppl.2512","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.2512","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.15_suppl.2512","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070570779","display_name":"Amita Patnaik","orcid":"https://orcid.org/0000-0002-4144-2193","observed_orcids":["https://orcid.org/0000-0002-4144-2193"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amita Patnaik","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109399966","display_name":"Soonmo Peter Kang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Soonmo Peter Kang","raw_affiliation_strings":["Merck & Co., Inc., Rahway, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., Rahway, NJ","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060992997","display_name":"Anthony W. Tolcher","orcid":"https://orcid.org/0000-0002-6322-9721","observed_orcids":["https://orcid.org/0000-0002-6322-9721"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony W. Tolcher","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073134832","display_name":"Drew Warren Rasco","orcid":"https://orcid.org/0009-0009-6619-2854","observed_orcids":["https://orcid.org/0009-0009-6619-2854"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Drew Warren Rasco","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022467575","display_name":"Kyriakos P. Papadopoulos","orcid":"https://orcid.org/0000-0002-0667-2620","observed_orcids":["https://orcid.org/0000-0002-0667-2620"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kyriakos P. Papadopoulos","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012209573","display_name":"Muralidhar Beeram","orcid":"https://orcid.org/0009-0002-6603-3780","observed_orcids":["https://orcid.org/0009-0002-6603-3780"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Muralidhar Beeram","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001759866","display_name":"Ronald L. Drengler","orcid":"https://orcid.org/0009-0003-2337-534X","observed_orcids":["https://orcid.org/0009-0003-2337-534X"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald Drengler","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100427120","display_name":"Cong Chen","orcid":"https://orcid.org/0000-0003-0875-7473","observed_orcids":["https://orcid.org/0000-0003-0875-7473"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cong Chen","raw_affiliation_strings":["Merck & Co., Inc., North Wales, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., North Wales, PA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103604982","display_name":"Lon S. Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lon Smith","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Crystal Perez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Crystal Perez","raw_affiliation_strings":["South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072448285","display_name":"Kevin Gergich","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin Gergich","raw_affiliation_strings":["Merck & Co., Inc., North Wales, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck & Co., Inc., North Wales, PA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063172978","display_name":"Manfred Lehnert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Manfred Lehnert","raw_affiliation_strings":["Merck, Rahway, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Merck, Rahway, NJ","institution_ids":["https://openalex.org/I1285764155"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":82,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":"15_suppl","first_page":"2512","last_page":"2512"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":1.0},{"id":"https://openalex.org/keywords/anti-pd-1-monoclonal-antibody","display_name":"anti-PD-1 monoclonal antibody","score":0.9509999752044678},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8289999961853027},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8190000057220459},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6779999732971191},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7429999709129333},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.968999981880188},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.9430000185966492},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.847000002861023},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.968999981880188},{"id":"https://openalex.org/keywords/rectal-cancer","display_name":"rectal cancer","score":0.9580000042915344},{"id":"https://openalex.org/keywords/sarcoma","display_name":"sarcoma","score":0.8880000114440918},{"id":"https://openalex.org/keywords/carcinoid-tumor","display_name":"carcinoid tumor","score":0.6679999828338623},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.5920000076293945}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.957595705986023},{"id":"https://openalex.org/C2777054765","wikidata":"https://www.wikidata.org/wiki/Q6402731","display_name":"Dysgeusia","level":3,"score":0.6644220948219299},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6591804027557373},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5668413043022156},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5543053150177002},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.5218804478645325},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5113053321838379},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4841190278530121},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.4745284616947174},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.4685099124908447},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.4427710771560669},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4373893141746521},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4297848343849182},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4225044250488281},{"id":"https://openalex.org/C2779399171","wikidata":"https://www.wikidata.org/wiki/Q1483951","display_name":"Malignancy","level":2,"score":0.41672825813293457},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.4112604856491089},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.36885207891464233},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3588297367095947},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2911113500595093},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2012.30.15_suppl.2512","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.2512","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.15_suppl.2512","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8799999952316284}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2487649631","https://openalex.org/W4319827755","https://openalex.org/W3215044659","https://openalex.org/W2799275431","https://openalex.org/W2519469881","https://openalex.org/W3041652591","https://openalex.org/W4281695136","https://openalex.org/W2738397398","https://openalex.org/W2617468510","https://openalex.org/W3032149558"],"abstract_inverted_index":{"2512":[0],"Background:":[1],"Programmed":[2],"death-1":[3],"(PD-1)":[4],"is":[5,19],"an":[6,87],"inhibitory":[7],"T-cell":[8],"coreceptor":[9],"that":[10],"may":[11],"lead":[12],"to":[13,65,97,267],"suppression":[14],"of":[15,49,69,80,156,196,233,260],"antitumor":[16,31,47,261],"immunity.":[17],"MK-3475":[18,28,249],"a":[20,154,227],"humanized":[21],"monoclonal":[22],"IgG4":[23],"antibody":[24],"against":[25],"PD-1.":[26],"Preclinically,":[27],"has":[29],"shown":[30,211],"activity":[32,48,262],"in":[33,59,212,241],"multiple":[34,100],"tumor":[35,234],"types.":[36],"This":[37],"first-in-human":[38],"phase":[39],"I":[40],"trial":[41],"explored":[42],"safety,":[43,270],"PK,":[44,271],"PD,":[45],"and":[46,83,90,188,230,272],"MK-3475.":[50],"Methods:":[51],"An":[52],"open-label,":[53],"dose":[54,89,123,257],"escalation":[55],"study":[56],"was":[57,108,198,239,250,263],"conducted":[58,109],"patients":[60,71,94,244],"with":[61,220,245],"advanced":[62,246],"malignancy":[63],"refractory":[64],"standard":[66],"therapy.":[67],"Cohorts":[68],"3-6":[70],"were":[72,95,159,206],"enrolled":[73],"(3+3":[74],"design)":[75],"at":[76,121,280],"escalating":[77],"IV":[78],"doses":[79,101,158,173],"1,":[81,93],"3,":[82],"10":[84],"mg/kg.":[85],"Following":[86],"initial":[88],"28-day":[91],"Cycle":[92],"allowed":[96],"subsequently":[98],"receive":[99],"given":[102],"every":[103,110],"2":[104,194],"wks.":[105],"Radiographic":[106],"assessment":[107],"8":[111],"wks":[112],"using":[113],"RECIST":[114],"1.1":[115],"guidelines.":[116],"Results:":[117],"Nine":[118],"patients,":[119],"3":[120,205,242,255],"each":[122],"level,":[124],"completed":[125],"the":[126,213,281],"dose-limiting":[127],"toxicity":[128],"(DLT)":[129],"period":[130],"(28":[131],"d).":[132],"Patients":[133],"had":[134,226],"non\u2013small":[135],"cell":[136],"lung":[137],"cancer":[138,142],"(NSCLC,":[139],"n=3),":[140],"rectal":[141],"(n=2),":[143,180],"melanoma":[144],"(MEL,":[145],"n=2),":[146],"sarcoma":[147],"(n=1),":[148,182,184,187],"or":[149],"carcinoid":[150],"(n=1).":[151,190],"To":[152],"date,":[153],"total":[155],"63":[157],"administered":[160],"(median":[161],"7/patient;":[162],"max":[163],"12)":[164],"without":[165,252],"DLT.":[166],"Drug-related":[167],"adverse":[168],"events":[169],"(AEs)":[170],"across":[171,254],"all":[172],"included":[174],"Grade":[175,193,204],"1":[176,218],"fatigue":[177],"(n=3),":[178],"nausea":[179],"diarrhea":[181],"dysgeusia":[183],"breast":[185],"pain":[186],"pruritus":[189,197],"One":[191],"drug-related":[192,201],"AE":[195],"reported.":[199],"No":[200],"AEs":[202],"\u2265":[203],"observed.":[207,264],"PK":[208],"data":[209,276],"are":[210],"table.":[214],"Based":[215],"on":[216,222],"RECIST,":[217],"patient":[219],"MEL":[221],"therapy":[223],">6":[224],"mths":[225],"partial":[228],"response,":[229],"preliminary":[231],"evidence":[232],"size":[235],"reduction":[236],"(stable":[237],"disease)":[238],"observed":[240],"additional":[243,269],"cancer.":[247],"Conclusions:":[248],"well-tolerated":[251],"DLT":[253],"tested":[256],"levels.":[258],"Evidence":[259],"Enrollment":[265],"continues":[266],"obtain":[268],"efficacy":[273],"data;":[274],"updated":[275],"will":[277],"be":[278],"presented":[279],"meeting.":[282],"[Table:":[283],"see":[284],"text]":[285]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":24},{"year":2014,"cited_by_count":24},{"year":2013,"cited_by_count":18},{"year":2012,"cited_by_count":7}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}